603127 昭衍新药
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入316,13510.02%1,657,6242,018,3342,376,4872,267,971
减:营业总成本334,23015.95%1,663,2151,763,7481,622,0101,418,766
    其中:营业成本251,37222.54%1,314,3121,444,5601,363,7011,181,660
               财务费用(12,816)-32.98%(66,802)(99,773)(151,091)(154,682)
               资产减值损失(13,705)-57.82%(156,761)(66,540)(31,232)(2,792)
公允价值变动收益283,026329.64%447,560(127,049)(245,642)349,567
投资收益4,571269.84%18,01436,0129,62813,022
    其中:对联营企业和合营企业的投资收益------15,471(3,069)(2,691)
营业利润255,919418.24%337,991104,347507,0961,225,639
利润总额256,055418.50%337,493104,039506,9501,240,002
减:所得税费用17,704114.22%39,65134,284115,398166,802
净利润238,351479.66%297,84369,755391,5531,073,200
减:非控股权益(5)19,296.03%1(4,320)(5,440)(1,057)
股东净利润238,357479.67%297,84174,075396,9931,074,257

市场价值指针
每股收益 (元) *0.320540.00%0.4000.1000.5301.440
每股派息 (元) *----0.1200.0300.1600.400
每股净资产 (元) *11.4195.52%11.10810.77911.04015.277
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容